----item----
version: 1
id: {1CED8EE8-C7B9-4849-9F52-56A10F1EB074}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/05/15/Waldheim Pharmazeutikas Austria HIV2 confirmatory well on its way through FDA
parent: {166B4D89-6B6A-4D16-8DA9-761C7F941ECD}
name: Waldheim Pharmazeutikas Austria HIV2 confirmatory well on its way through FDA
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 2ec5f77f-d302-4ebf-bf74-2ad40815519d

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 550

<p>Waldheim Pharmazeutika (Austria) says the US FDA has accepted Product and Establishment Licence Applications for its HIV-2 confirmatory immunofluorescence assay, Fluorognost HIV-2 IFA. "In spite of its huge review burden, the FDA Center of Biologics has sent the filing letter very quickly, and without requesting any further information at this point," said Dr Hermann Mucke, managing director of Waldheim's Diagnostics Division. "We believe that the Agency wants an approved HIV-2 confirmatory test out on the US market as soon as possible."</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 81

Waldheim Pharmazeutika's (Austria) HIV-2 confirmatory well on its way through FDA
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 794

<p>Waldheim Pharmazeutika (Austria) says the US FDA has accepted Product and Establishment Licence Applications for its HIV-2 confirmatory immunofluorescence assay, Fluorognost HIV-2 IFA. "In spite of its huge review burden, the FDA Center of Biologics has sent the filing letter very quickly, and without requesting any further information at this point," said Dr Hermann Mucke, managing director of Waldheim's Diagnostics Division. "We believe that the Agency wants an approved HIV-2 confirmatory test out on the US market as soon as possible."</p><p>The company, which is part of the closely held Sanochemia group of companies, has been selling the HIV-1 version of the Fluorognost test in the US since 1992, after it became the first overseas facility licensed to manufacture HIV tests.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{12C97AC3-D19F-4DF0-B0DB-B9C82176F72C}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 77

Waldheim Pharmazeutikas Austria HIV2 confirmatory well on its way through FDA
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950515T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950515T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950515T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052629
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 81

Waldheim Pharmazeutika's (Austria) HIV-2 confirmatory well on its way through FDA
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

254438
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184235Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

2ec5f77f-d302-4ebf-bf74-2ad40815519d
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184235Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
